Development and in vivo characterization of the first peptide-based 99mTc-Nitrido-radiopharmaceuticals for FAP-targeted SPECT imaging
This study successfully developed and characterized the first peptide-based 99mTc-nitrido radiopharmaceuticals targeting Fibroblast Activation Protein (FAP), demonstrating that the choice of bisphosphinoamine ligand significantly influences biological profiles, with the [99mTc][Tc(N)PNP3]-cysFAP compound showing the most favorable in vivo performance for SPECT imaging of FAP-positive tumors.